Clinical Trial Detail

NCT ID NCT03810105
Title A Study of Olaparib and Durvalumab in Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

prostate cancer

Therapies

Durvalumab + Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST